CPHI Milan 2
CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

PCI Announces Appointment to its Manufacturing Business Development Team

Leading pharmaceutical outsourcing services provider PCI Pharma Services has announced the appointment of Jennifer Goldberg to its Manufacturing Business Development team.
 
Jennifer joins PCI as Senior Account Executive, with responsibility for developing opportunities and building sales in PCI’s US West Coast territory to ensure continued growth and success in this key market.  Jennifer has an extensive background in drug development and manufacturing, with varying roles in business development at leading CMOs over a successful 20-year career.
 
Commenting on Jennifer’s appointment, Rob Jones, Business Development Director International at PCI, said: “We are delighted to welcome Jennifer to PCI.  She brings a tremendous amount of knowledge, experience and credibility to our business.  We look forward to her valuable contributions to the organization and in providing our customers the industry leading experience.”
 
Jennifer said of her new role: “I’m excited to join PCI Pharma Services and apply my previous experience to my new position. I have a long history of working in sales and business development in this space.  I am looking forward to using my knowledge to help clients overcome their difficult drug development challenges and realize successful commercialization of their lifesaving medicines.”
 
PCI recently announced the investment in a fully contained Xcelodose® 600S unit in support of drug development for highly potent molecules.  The technology allows for drug-in-capsule delivery in early phase clinical trials allows clients to realize significant reductions in development timelines as well as reduce costs by minimizing formulation development activity and reducing use of costly API.  The Xcelodose® 600S technology is enhanced by a PCI-designed, custom-built XceloprotectTM containment system providing an early stage development solution for the management of highly potent molecules.
 
The company also recently announced acquisition of Millmount Healthcare, expanding its presence into Ireland and the European Union, adding four facilities in the greater Dublin area.
 

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026